Botox manufacturer to be bought for $63 billion

In the US pharmaceutical market, a new mega-deal: AbbVie (high-priced drugs for HIV, hepatitis C, multiple sclerosis and other diseases) buys the Irish company Allergan, the manufacturer of the cosmetic drug Botox, for $63 billion, writes the Financial Times .

• The company was bought with a large premium to the market - 45%.
• The purchase should support sales of AbbVie after the world's top-selling antirheumatoid drug adalimumab (Humira) loses patent protection. Since the start of sales in 2002, it has brought the company $120 billion. Analogues of Humira are already being registered all over the world, and the Russian Biocad has done the same.
• AbbVie and Allergan plan to generate $48 billion in revenue per year and pay off loans taken on the deal with future profits.
• In 2016, the American Pfizer refused to buy Allergan for $150 billion. The deal could have become the largest in the history of the pharmaceutical market, but it was cut down by the American regulator: the combined company wanted to move its headquarters to Ireland and thereby halve Pfizer's taxes. Since then, Allergan stock has been falling.
• For the same reason, AbbVie itself refused to buy the Irish biopharmaceutical company Shire for $54.8 billion in 2014.